Long-acting GHRH analog
CJC-1295 with DAC
In healthy adults, CJC-1295 with DAC had an estimated half-life of 5.8 to 8.1 days after one injection (Teichman and colleagues, 2006).1 The app lists about 8 days.
CJC-1295 with DAC after one dose: 50% at ~8 days, 25% at 16 days, 12.5% at 24 days.
Drawn from the half-life in the app's model, ~8 days. The model's figures
- Compound
- CJC-1295 with DAC
- Symbol
- DAC
- Family
- Growth hormone peptides
- Parts
- 13
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
CJC-1295 with DAC is a modified form of growth hormone-releasing hormone (GHRH). Teichman and colleagues name it "drug affinity complex-GH-releasing factor (DAC-GRF; CJC-1295, ConjuChem, Inc., Montréal, Canada)" and describe a reactive chemical that enables binding to serum albumin after subcutaneous injection.1
In two placebo-controlled trials in healthy adults aged 21 to 61 (Teichman and colleagues, Journal of Clinical Endocrinology and Metabolism, 2006), the first gave a single subcutaneous injection, after which mean growth hormone (GH) concentrations were 2- to 10-fold higher for 6 days or more and the estimated half-life was 5.8 to 8.1 days.1 The work was supported by ConjuChem, Inc., and three of the six authors list ConjuChem as their affiliation.1
Dominikowski and colleagues (Frontiers in Endocrinology, 2026) state that "neither CJC-1295 variant is approved as a therapeutic agent by major regulatory authorities (e.g., FDA, EMA)".2 The TGA names it among examples of unapproved peptide products,3 WADA prohibits it at all times,4 ClinicalTrials.gov lists a phase 2 trial of CJC 1295 in HIV-associated visceral obesity as terminated,5 and a ConjuChem press release reports a patient's death in a phase 2 trial of DAC:GRF in HIV lipodystrophy that the company said it had terminated; the two documents do not say whether they describe one study.6
How it works
Sources in this part
Teichman and colleagues describe the core of the molecule as a fragment of GHRH with four amino-acid substitutions "that serve to render the compound more resistant to proteolytic cleavage". It is linked through lysine to maleimidoproprionic acid, a chemical that binds unpaired thiol groups, and "the predominant free thiol group available for binding after parenteral administration is the single unpaired cysteine (cysteine 34) in serum albumin".1
The paper states that "at least 90% of CJC-1295 binds covalently to albumin in this fashion", and the statement that no other chemical species have been found bound cites "data on file, ConjuChem, Inc." The authors give native GHRH a half-life of 7 minutes and call its short half-life a major limitation.1
Animal studies include Jetté and colleagues (Department of Research, ConjuChem Inc., Endocrinology, 2005), who gave CJC-1295, the best of three compounds tested, subcutaneously to normal male Sprague Dawley rats and reported a "4-fold increase in GH area under the curve over a 2-h period compared with hGRF(1-29)" and presence in plasma "beyond 72 h".7 Alba and colleagues (Johns Hopkins University, American Journal of Physiology, 2006) gave 2 µg of CJC-1295 for 5 weeks to mice lacking GHRH: daily dosing gave normal body weight and length, and dosing every 48 or 72 hours reached higher weight and length than placebo "without full growth normalization".8 The paper's co-authors include Lawrence and Castaigne, listed at ConjuChem in Teichman and colleagues' paper, and Frohman; the PubMed record states no funder.8,1 These are rat and mouse results, not human ones.
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~8 days
- Bioavailability
- 95%
- Typical dose
- 1000–2000 mcg/week
- Route
- SubQ
- Time to peak
- ~48 h
Sources in this part
The estimated half-life of CJC-1295 with DAC was 5.8 to 8.1 days across four single-dose groups in the first trial of Teichman and colleagues, and 5.4 to 9.2 days in subjects sampled for up to 14 days in their second trial.1 The app's figure is about 8 days (192 hours); Ionescu and Frohman write "half-life = 8 d" and Sackmann-Sala and colleagues "8 – 10 days in humans".9,10
| Measure | The app | Reported in studies |
|---|---|---|
| Half-life | ~8 days (192 hours) | Mean 5.8–8.1 days after one injection of 30 to 250 µg/kg; 5.4–9.2 days in the multiple-dose trial1 |
| Time to peak | ~48 hours | CJC-1295 in plasma: 1 to 1.5 hours (single dose) or 0.5 to 2.0 hours (multiple dose). Median GH peak within 1 hour (4 hours at 250 µg/kg). IGF-I peak 2 to 3 days, and 4 days after 250 µg/kg1 |
| Bioavailability | 95% | No bioavailability figure appears in the paper's pharmacokinetic results1 |
| Duration of effect | ~21 days (504 hours) | GH above baseline for 6 days or more after one injection. IGF-I: 9 to 11 days in the summary and results, but "up to 14 d", "at least 2 wk" at the two highest doses and "nearly 2 wk" elsewhere in the paper, so its own figures differ. After repeated injections IGF-I stayed above baseline through day 281 |
| Clearance and volume of distribution | None listed | Clearance 0.04 to 0.05 L/h/kg and volume of distribution 8.1 to 13.8 L/kg across the four single-dose groups1 |
The chart is an illustration drawn from the app's half-life of 192 hours and time to peak of 48 hours, not from trial concentrations; in the paper, CJC-1295 peaked in plasma 0.5 to 2 hours after injection.1 The weekly and every-14-days intervals are those given to the multiple-dose groups of Teichman and colleagues' second trial.1
Level over 6 weeks
Level, as a share of the peak after one 1000 mcg dose
As studied: every 7 days (3 injections, days 0, 7, 14)1, every 14 days (2 injections, days 0 and 14)1.
An illustration from a pharmacokinetic model using a half-life of 192 hours (8 days). It is not a measured level or a suggested dose.
Human studies
A search of PubMed on 16 November 2026 for CJC-1295 in the title or summary text returned 35 records, 2 of them typed as clinical trials (Teichman and colleagues; Ionescu and Frohman). A ClinicalTrials.gov search for CJC-1295 the same day returned 1 study, which was terminated.5
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Teichman and colleagues, 2006, study 11 | Randomized, double-blind, placebo-controlled, single dose; 28 days; Miami | Healthy adults aged 21–61: four groups of 6 (5 active, 1 placebo) and 18 more at 125 µg/kg (15 active) | One subcutaneous injection of 30, 60, 125 or 250 µg/kg | Mean GH 2- to 10-fold above baseline through day 6; IGF-I elevated 9–11 days; GH area under the curve above placebo at 60, 125 and 250 µg/kg only; adverse events in 94% (33 of 35) on CJC-1295 and 29% (2 of 7, pooled placebo) on placebo |
| Teichman and colleagues, 2006, study 21 | Randomized, double-blind, placebo-controlled, multiple dose; 49 days; Utrecht | 24 healthy adults in four groups of 6 (5 active, 1 placebo) | Two injections (days 0, 14) of 30 or 60 µg/kg, or three injections (days 0, 7, 14) of 30 or 20 µg/kg | IGF-I above baseline through day 28; pre-dose elevation reached significance only in the 20 µg/kg group (P < 0.03) |
| Ionescu and Frohman, 20069 | GH sampled every 20 minutes for 12 hours, before and 1 week after injection | Healthy men aged 20–40 (number not given in the PubMed record) | One injection of 60 or 90 µg/kg | Trough GH 7.5-fold higher (P < 0.0001); mean GH +46%; IGF-I +45%; pulse frequency and magnitude unaltered |
| Sackmann-Sala and colleagues, 200910 | Serum protein analysis before and 1 week after injection | 11 healthy men aged 20–34, a subset of the larger cohort | One subcutaneous injection of 60–90 µg/kg | Of 97 protein spots present in all subjects, 5 changed (2 decreased, 3 increased) |
| Registry entry NCT00267527 (ConjuChem), 2005–20065 | Randomized, double-blind, placebo-controlled phase 2; 12 weeks of treatment and 6 weeks of follow-up planned | Adults aged 18–65 with HIV-associated visceral obesity; enrollment 120 | Low dose, high dose or placebo (amounts not stated) | Terminated; no results posted |
| ConjuChem press release, 8 August 2006 (no registry number)6 | Multi-center, randomized, placebo-controlled, double-blind phase 2 in HIV lipodystrophy; once-weekly dosing for 12 weeks, then 6 weeks of follow-up | Enrollment of 192 completed; one death at a site in Argentina | DAC:GRF once weekly (dose not stated) | Company reported the patient's death after the 11th weekly dose and said it had terminated the study; not stated whether it is the registry trial |
Deeper analysis: Teichman and colleagues, 2006
Teichman and colleagues (WinPharm Associates, ConjuChem Inc. and the University of Illinois, Journal of Clinical Endocrinology and Metabolism, 2006) ran two randomized, placebo-controlled, double-blind, ascending-dose trials of 28 and 49 days in healthy men and women aged 21 to 61 (44% men) with a body mass index of 30 or less and normal IGF-I for age and sex. The main outcome measures were peak concentrations and area under the curve of GH and IGF-I, and pharmacokinetic parameters for CJC-1295.1
After a single injection, mean GH rose 2- to 10-fold above a pre-injection mean of 0.7 to 1.1 ng/mL, and mean IGF-I, from pre-injection values of 123 to 152 ng/mL, stayed elevated for 9 to 11 days. The paper states that "IGF-I levels exceeded the age- and gender-adjusted normal ranges only in subjects receiving 250 μg/kg CJC-1295".1
GH area under the curve differed from placebo only at 60, 125 and 250 µg/kg, and in the second trial the pre-dose IGF-I elevation reached significance only in the 20 µg/kg weekly group (P < 0.03; P < 0.07 in the 30 µg/kg weekly group). Cortisol, prolactin, TSH and LH showed no significant increase after a single 60 µg/kg injection. The authors conclude that CJC-1295 "was safe and generally well tolerated, particularly at doses of 30 and 60 μg/kg".1
The work "was supported by ConjuChem, Inc.", and the affiliations list three authors at ConjuChem. The paper has no separate limitations section. Its discussion states that "the most appropriate dosing interval will be determined based on actual efficacy and safety data from longer-term therapeutic studies in patients with various clinical conditions".1 Group comparisons used ANOVA and/or a one-tailed t test.1
Deeper analysis: Ionescu and Frohman, 2006
The authors state their objective as "to assess GH pulsatility after a single injection of CJC-1295 and determine which GH secretion parameters correlated to the increase in IGF-I production". In healthy men aged 20 to 40, 1 week after one injection of 60 or 90 µg/kg, pulse frequency and magnitude were unaltered, trough GH levels were 7.5-fold higher (P < 0.0001), mean GH was 46% higher (P < 0.01) and IGF-I 45% higher (P < 0.001), with no significant difference between the two doses and no correlation of the IGF-I rise with any GH secretion parameter.9 The authors conclude that "long-acting GHRH preparations may have clinical utility in patients with intact pituitary GH secretory capability".9 The PubMed record does not give the number of men, the funder or the authors' own limitations, and the study compares each man with his own earlier overnight sample, with one time point after injection.9 Sackmann-Sala and colleagues describe their 11 men as a subset of this cohort, and their work was supported in part by grants from WADA and ConjuChem Inc., among others.10
The terminated phase 2 trial in HIV
The ClinicalTrials.gov entry NCT00267527, sponsored by ConjuChem, describes the phase 2 study in adults aged 18 to 65 with HIV-associated visceral obesity and a body mass index above 24 and below 30. It is listed as terminated, with a start in December 2005, a completion in September 2006, and no results posted.5
A ConjuChem press release of 8 August 2006 reports the findings of the company's own investigation into a death in its phase 2 trial of "DAC:GRF" in HIV lipodystrophy at a clinical site in Argentina; the release gives no registry number, and "DAC:GRF" is a name Teichman and colleagues give alongside CJC-1295. It states that the participant received the 11th weekly dose on 13 July, complained of chest discomfort about two hours later, had an acute myocardial infarction confirmed by electrocardiogram, and died about an hour later. The company gives the attending physician's most likely explanation as "asymptomatic coronary artery disease with plaque rupture and occlusion". ConjuChem indicated that it had terminated the study, and the release gives no stated reason for the termination.6,1 The release is the sponsor's own account; it gives an enrollment of 192 and the registry entry 120, and the two name the condition differently (lipodystrophy and visceral obesity), so the two documents do not establish that they describe one study.5,6
Doses reported in studies
The trials gave doses per kilogram of body weight rather than as a weekly total,1 and the app's typical dose is 1000–2000 mcg per week.
| Source | Dose | Schedule | People | Note |
|---|---|---|---|---|
| Teichman and colleagues, study 11 | 30, 60, 125 or 250 µg/kg | One subcutaneous injection | Healthy adults; 6 per group (5 active, 1 placebo), plus 18 at 125 µg/kg | Authors call 125 µg/kg "well tolerated", though both early discontinuations (injection site reactions) were at 125 and events at 250 were moderate; "particularly" well tolerated at 30 and 60 µg/kg |
| Teichman and colleagues, study 21 | 20, 30 or 60 µg/kg per injection | Days 0 and 14 (30 or 60), or days 0, 7 and 14 (30 or 20) | Healthy adults; 6 per group (5 active, 1 placebo) | Authors: "a minimum dosing interval of 7 d appears reasonable" |
| Ionescu and Frohman; Sackmann-Sala and colleagues9,10 | 60 or 90 µg/kg (60–90 µg/kg in the second report) | One injection | Healthy men aged 20–40 and 20–34 (the second a subset of the first cohort) | Ionescu and Frohman report no significant difference between the two doses |
| Online forum descriptions, as summarized by Dominikowski and colleagues2 | 1–2 mg per week | 1 or 2 injections | Not applicable | The review presents such figures "as anthropological and behavioural descriptors", not as clinical guidance |
Side effects reported
In the single-dose trial of Teichman and colleagues, adverse events were reported in 33 (94%) of the subjects on CJC-1295 and 2 (29%) of the subjects on placebo; "all were of mild to moderate severity, and none required medical intervention to resolve". Injection site reactions occurred in about 70% of those on CJC-1295 and "rarely" on placebo, with residual induration lasting up to 5 days, and transient urticarial rashes at the injection site occurred in almost 30%. Headache occurred in 63%, diarrhea in 43% and systemic vasodilatory reactions (flushing, warmth, transient hypotension) in 30%; of these, only headache occurred on placebo (14%). The paper states that these were more common at 125 or 250 µg/kg, with events at 250 µg/kg moderate in severity and resolving spontaneously after a few hours.1
In the multiple-dose trial, injection site reactions were reported in all subjects on CJC-1295, all described as mild and up to 10 cm in diameter, and mild injection site erythema occurred in three of four placebo subjects. Flushing occurred only on CJC-1295, in 40% after low-dose and 100% after high-dose injections. The paper's list of other events, placed after its multiple-dose results, gives transient loose stools or diarrhea in 45% and 100% of the "125 and 250 μg/kg groups, respectively" (doses used in the single-dose trial, so the labels are inconsistent), nausea or abdominal pain in 20%, and headache from 20% to 80% by dose group (placebo: 14% in study 1, 50% in study 2).1
Three subjects discontinued early: two in the first trial (both at 125 µg/kg), 5 and 22 days after dosing, because of mild injection site reactions, and one in the second trial, 6 days after "multiple mild adverse effects following a single injection of 30 μg/kg". One subject reported mild, transient involuntary leg muscle contractions and some loss of coordination after the second biweekly 30 µg/kg injection, and two had transient dizziness and hypotension after a first 30 µg/kg injection. The paper reports "no consistent changes in blood or urine laboratory values, including glucose levels and liver function studies, or in electrocardiographic findings", no significant antibody formation, and "No serious adverse reactions" in either trial.1
Teichman and colleagues note that growth hormone doses of 2–3 mg per day or greater are associated with edema, arthralgias and glucose intolerance in HIV-associated metabolic conditions, and that "none of the subjects experienced these adverse effects" in their own healthy-adult studies of 28 and 49 days.1 Dominikowski and colleagues write that fluid retention syndromes are "documented in peer-reviewed human studies exclusively for tesamorelin, with comparable findings not identified in the available peer-reviewed literature for the other peptides discussed, although mechanistic overlap within the somatotropic axis warrants cautious interpretation", and that for CJC-1295 with DAC "No long term safety data available".2
The FDA page that lists CJC-1295 states: "FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited." The text gives no number of reports.11 The sponsor's account of a death in the terminated phase 2 trial is given under human studies above.6
Bloodwork and markers
Sources in this part
The app lists IGF-1, blood glucose and insulin as markers for this compound. Teichman and colleagues measured GH and IGF-I by radioimmunoassay, ran serum chemistry, hematology and urinalysis as safety assessments, and measured cortisol, prolactin, TSH and LH in subjects given 60 µg/kg.1
Regulatory and anti-doping status
| Body | Statement | Date |
|---|---|---|
| FDA11 | CJC-1295 appears under "Bulk drug substances nominated but withdrawn", a list described as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators". The entry says compounded drugs containing CJC-1295 "may pose risk for immunogenicity for certain routes of administration", that FDA "has identified serious adverse events" including "increased heart rate and systemic vasodilatory reaction", and that "Available clinical data are limited." | Page current as of 22 April 2026 |
| TGA (Australia)3 | Names CJC-1295 among examples of unapproved peptide products and states that "Unapproved peptide products have not been assessed by the TGA for safety, quality or effectiveness." | Published 13 April 2026 |
| WADA4 | Section S2.2.4 of the 2026 Prohibited List names CJC-1295 among GHRH analogues; section S2 is prohibited at all times, in and out of competition | In force 1 January 2026 |
The review words the FDA position differently from the FDA page: it states that "FDA listed it as prohibited on 'Category 2 of Bulk Drug Substances List' due to vasodilatatory reactions and tachycardia reports".2 The review's authors report no external funding and no conflict of interest.2
What is not known
Sources in this part
Teichman and colleagues' main outcome measures were GH and IGF-I concentrations and pharmacokinetic parameters, and the 2026 review grades the evidence for CJC-1295 with DAC as "Phase I PK/PD studies in healthy adults; no controlled efficacy data".1,2 Among the 35 records returned by the search of PubMed on 16 November 2026, none has a title describing a trial of CJC-1295 with a body-composition result, and the one phase 2 study in the registry is terminated with no results posted.5
Teichman and colleagues' trials followed subjects for 28 and 49 days, and Dominikowski and colleagues state that "No long term safety data available" for the compound.1,2 Teichman and colleagues' pharmacokinetic results give no bioavailability figure and no half-life measured over more than three injections, and the PubMed records of Ionescu and Frohman, Jetté and colleagues and Alba and colleagues give no bioavailability figure.1 The no-DAC form is a separate matter: the review states that it "remains essentially uncharacterised in the peer-reviewed human literature" and lists its human half-life as not reported.2
Frequently asked questions
What is the half-life of CJC-1295 with DAC?
What does DAC mean in CJC-1295?
DAC stands for "drug affinity complex", from Teichman and colleagues' name for the whole compound, "drug affinity complex-GH-releasing factor" (DAC-GRF).1 They describe the albumin-binding part as maleimidoproprionic acid linked through lysine, a reactive chemical that enables binding to serum albumin after injection; Dominikowski and colleagues call it the DAC modification.1,2
What is the difference between CJC-1295 with DAC and without DAC?
The with-DAC form carries the albumin-binding modification: Dominikowski and colleagues write that "The DAC modification enables binding to circulating albumin, markedly prolonging exposure".2 The same review states that the without-DAC form "remains essentially uncharacterised in the peer-reviewed human literature".2
Does CJC-1295 with DAC raise growth hormone and IGF-1?
What side effects were reported for CJC-1295 with DAC in people?
In the single-dose trial, adverse events, all of mild to moderate severity, were reported in 94% (33 of 35) of subjects on CJC-1295 and 29% (2 of 7) on placebo, including injection site reactions (about 70%), headache (63%; 14% on placebo), diarrhea (43%) and systemic vasodilatory reactions (30%).1 The paper reports no serious adverse reactions in either trial and three early discontinuations.1 FDA states it has identified serious adverse events including increased heart rate and systemic vasodilatory reaction.11
Is CJC-1295 with DAC approved?
Is CJC-1295 banned by WADA?
The WADA 2026 Prohibited List names CJC-1295 under S2.2.4, growth hormone releasing factors, within section S2, which is prohibited at all times, in and out of competition.4
Did a CJC-1295 clinical trial report a death?
ConjuChem's press release of 8 August 2006 reports that a patient died after the 11th weekly dose in its phase 2 trial of DAC:GRF in HIV lipodystrophy, and says the company had terminated the study; the release gives no stated reason for the termination.6 The company reports the attending physician's most likely explanation as asymptomatic coronary artery disease with plaque rupture and occlusion; this is the sponsor's own account.6
Has CJC-1295 with DAC been studied together with ipamorelin?
Dominikowski and colleagues write that "controlled clinical evidence supporting synergy or meaningful body-composition outcomes in healthy individuals remains limited" for the combination, which they describe as discussed "in off-label fitness discourse", typically with the non-DAC form.2 The pair has its own page: CJC-1295 and ipamorelin.
Guides, tools and comparisons
- How many units of CJC-1295 DACA guide that answers a question on this compound.
- Calculator for CJC-1295 with DACA calculator set up for this compound.
- CJC-1295 with DAC vs no DACA side-by-side with another compound.
- Previous in Growth hormone peptides: CJC-1295 + IpamorelinThe compound before this one in the class.
- Next in Growth hormone peptides: Follistatin-315The compound after this one in the class.
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91:799-805. PMID 16352683
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) 2026. PMC13322892
- Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. TGA advisory
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force 1 January 2026. WADA 2026 list
- ConjuChem. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. ClinicalTrials.gov NCT00267527, status verified October 2006. NCT00267527
- ConjuChem Biotechnologies Inc. ConjuChem provides findings of DAC:GRF HIV lipodystrophy trial investigation. Press release, 8 August 2006 (NATAP copy, archived). Archived press release
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146:3052-8. PMID 15817669
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab 2006;291:E1290-4. PMID 16822960
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91:4792-7. PMID 17018654
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 2009;19:471-7. PMC2787983
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. FDA page